The MAP 2024 programme is now online!
MAP focuses on current and emerging approaches in precision oncology, highlights successes and challenges, and proposes potential solutions in clinical research and practice.
This event constitutes an excellent occasion to reunite basic scientists, people working on new technologies, medical doctors, and healthcare providers.
Our globally recognised experts in the field await you for three days of discussions on discoveries in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics.
Learning objectives
- Provide up-to-date information on the molecular characterisation and clonal evolution of solid tumours on different cancer populations
- Understand emerging technologies for cancer profiling, including artificial intelligence and data analysis
- Acquire a better understanding of mechanisms driving tumour expansion, metastatic dissemination and cross talk between malignancy, microenvironment and host
- Learn about new concepts of molecular tumour classification and biomarker-driven development of targeted therapeutics with their methodological and regulatory implications
Accreditation
ESMO-MORA:
The MAP Programme 16-18 October 2024 has been accredited with 21 cat.1 ESMO-MORA points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possesses the necessary skills and standards for the practice of medical oncology. See here for further details.
Disclaimer
ESMO is a scientific and professional, non-political and non-religious organisation. ESMO will not accept responsibility for any comments or remarks made during any of our events by session chairs, invited speakers, presenters, members or any other contributor, formally or informally, which might cause offence or be perceived as being biased.
The experts invited by ESMO as abstract Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.